Wed, Aug 14, 8:49 PM (153 days ago)
On August 13, 2024, AnaptysBio, Inc. entered into an underwriting agreement with TD Securities (USA) LLC and Leerink Partners LLC for a public offering of 2,750,498 shares of common stock at an offering price of $36.50 per share. The company anticipates gross proceeds of approximately $100 million from this offering, which is set to close on August 15, 2024, pending customary closing conditions. The proceeds are intended for general corporate purposes, including funding Phase III readiness for product candidates ANB032 and rosnilimab. This offering is conducted under a previously filed shelf registration statement with the SEC. The report includes forward-looking statements regarding the offering's proceeds and the company's future activities, which are subject to risks and uncertainties. The underwriting agreement and legal opinion related to the offering are included as exhibits in the report.